Institutional members access full text with Ovid®

Share this article on:

Safety Concerns Over an Osteoporosis Drug

Aschenbrenner, Diane S. MS, RN

AJN The American Journal of Nursing: November 2011 - Volume 111 - Issue 11 - p 23,24
doi: 10.1097/01.NAJ.0000407287.40125.eb
Drug Watch
  • The label for the osteoporosis drug Reclast has been revised to strengthen the warning concerning the risk of acute renal failure, a rare adverse effect.
  • Prior to administering the drug, nurses should assess patients for risk factors for acute renal failure: decreased creatinine clearance, older age, and dehydration.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch:

© 2011 Lippincott Williams & Wilkins, Inc.